The U.S. Food and Drug Administration has approved Gilenya, the first oral treatment for multiple sclerosis.
The U.S. Department of Health and Human Services announced that Medicare Part B premiums in 2012 will be lower than previously projected.
The Nobel Foundation has awarded Ralph Steinman of Canada, American Bruce Beutler and Jules Hoffmann of France the Nobel Medicine Prize for their discoveries concerning the body’s immune responses.
The U.S. Department of Health and Human Services (HHS) has launched a new initiative made possible by the Affordable Care Act to help primary care practices deliver higher-quality, more coordinated and patient-centered care.
Danish surgeons designed and conducted a randomized clinical trial to compare conventional mesh fixation using titanium tacks against fibrin sealant.
A new report by the U.S. Department of Health and Human Services examines the issues surrounding hospital stays for the uninsured.
A recent study showed satisfactory clinical response to intraveinous immunoglobulin was observed in 10 patients with severe and wide-spread epidermolysis.
A recent study confirmed the protective effect of 4% human serum albumin both on [mouse] survival and endothelial dysfuction.
A Phase III study of HyQ, an investigational facilitated subcutaneous immuneglobulin product for use inpatients with primary immunodeficiency, has produced top-line results.
The U.S. Food and Drug Administration and the Committee for Medicinal Products for Human Use in Europe have approved the return of Octagam 5% (human normal immunoglobulin 50 mg/ml) to the market. Marketing authorization was suspended in August 2010 in the U.S.
In July, 12 new medical diagnoses were added to the Social Security Administration’s Compassionate Allowances program.
Ischemic stroke hospitalization rates in adolescents and young adults ages 15 to 44 increased up to 37 percent between 1995 and 2008, according to a study conducted by researchers at the Centers for Disease Control and Prevention.